Astellas and Pfizer's Xtandi Meets Primary Endpoint in Ph III Trial of Metastatic Prostate Cancer

Astellas and Pfizer's Xtandi Meets Primary Endpoint in Ph III Trial of Metastatic Prostate Cancer

Source: 
CP Wire
snippet: 

Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and Pfizer Inc. (NYSE: PFE) today announced that the Phase 3 ARCHES trial evaluating Xtandi (enzalutamide) plus androgen deprivation therapy (ADT) in men with metastatic hormone-sensitive prostate cancer (mHSPC) met its primary endpoint, significantly improving radiographic progression-free survival (rPFS) versus ADT alone.